Brokers Issue Forecasts for Cabaletta Bio FY2025 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Cabaletta Bio in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings per share of ($2.19) for the year. The consensus estimate for Cabaletta Bio's current full-year earnings is ($2.34) per share.

Other equities research analysts also recently issued research reports about the company. TD Cowen raised Cabaletta Bio to a "strong-buy" rating in a research report on Friday, November 29th. Evercore ISI cut Cabaletta Bio from an "outperform" rating to an "inline" rating and decreased their target price for the stock from $15.00 to $6.00 in a report on Friday, December 20th. Wells Fargo & Company lowered shares of Cabaletta Bio from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $12.00 to $6.00 in a report on Thursday, December 19th. William Blair reiterated an "outperform" rating on shares of Cabaletta Bio in a research note on Monday, November 18th. Finally, HC Wainwright reissued a "buy" rating and issued a $25.00 price objective on shares of Cabaletta Bio in a research report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $24.38.

Cabaletta Bio Price Performance

CABA stock traded up $0.05 on Thursday, hitting $2.59. 997,765 shares of the company were exchanged, compared to its average volume of 1,548,546. Cabaletta Bio has a twelve month low of $1.76 and a twelve month high of $26.35. The business's fifty day moving average is $2.65 and its two-hundred day moving average is $4.30. The stock has a market capitalization of $126.60 million, a price-to-earnings ratio of -1.20 and a beta of 2.46.

Hedge Funds Weigh In On Cabaletta Bio

Institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Cabaletta Bio during the third quarter worth about $32,000. Point72 DIFC Ltd acquired a new stake in Cabaletta Bio during the 3rd quarter valued at approximately $33,000. Avanza Fonder AB acquired a new stake in Cabaletta Bio during the 4th quarter valued at approximately $40,000. China Universal Asset Management Co. Ltd. increased its holdings in Cabaletta Bio by 65.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,395 shares of the company's stock worth $44,000 after purchasing an additional 3,724 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of Cabaletta Bio in the 3rd quarter valued at approximately $67,000.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.